MNPR-101-Lu177

N/A

Report date: 2025/09/19 16:19:18

Base Information

Drug NameMNPR-101-Lu177
Drug Alias NameMNPR 101 lutetium-177MNPR 101 Lu 177MNPR 101-PCTA-177Lu177Lu-MNPR-101MNPR-101-PCTA-177Lu +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177Lu +[4] 
Mechanisms of ActionAnti-Urokinase plasminogen activator surface receptor
TargetsUrokinase plasminogen activator surface receptor
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsLung Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMonopar Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMonopar Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsLung Neoplasms +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A